These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15264432)

  • 1. Pharmacogenomics in breast cancer: current trends and future directions.
    Wajapeyee N; Somasundaram K
    Curr Opin Mol Ther; 2004 Jun; 6(3):296-301. PubMed ID: 15264432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
    Kaklamani V
    Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of genetic variability on drug response in conventional breast cancer treatment.
    Wiechec E; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):122-30. PubMed ID: 19836373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
    Lee W; Lockhart AC; Kim RB; Rothenberg ML
    Oncologist; 2005 Feb; 10(2):104-11. PubMed ID: 15709212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
    Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
    Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genomic markers and anticancer chemotherapy].
    Nishiyama M
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenomics genomics approaches to optimizing drug therapy].
    Shi J; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Apr; 19(2):156-8. PubMed ID: 11941596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer.
    Miki Y
    Breast Cancer; 2010 Apr; 17(2):97-102. PubMed ID: 20013078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
    Nagasaki K; Miki Y
    Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effective treatment strategy in elderly breast cancer patients].
    Boér K
    Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics/genomics and personalized medicine.
    Sadée W; Dai Z
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R207-14. PubMed ID: 16244319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics for individualized cancer chemotherapy.
    Efferth T; Volm M
    Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.